News

Fluent, Inc. Welcomes Adrian Stack to Propel Product Innovation

Fluent, Inc. Welcomes Adrian Stack to Propel Product Innovation

Exciting Leadership Change at Fluent, Inc.

Fluent, Inc. (NASDAQ: FLNT), an established leader in commerce media solutions, has recently appointed Adrian Stack as their new Chief Product Officer. This strategic move is set to invigorate the Company's approach to AI-powered innovations, focusing on enriching consumer engagement while bolstering success rates for partners and advertisers.

Adrian Stack: A Visionary Leader

Adrian Stack brings over 15 years of robust experience in product development. His expertise lies in integrating AI technologies to foster growth, which is evident from his previous roles. Most notably, he was instrumental at Zillow, overseeing Data Engineering within the realms of Data Science and AI. Additionally, during his tenure as SVP of Product at Rokt, he contributed significantly to the expansion of the commerce media business, managing areas such as data engineering, machine learning, and analytics.

The CEO's Perspective

Expressing enthusiasm about Stack's arrival, Don Patrick, the Chief Executive Officer of Fluent, stated, “We’re thrilled to welcome Adrian as we continue to build a world-class product team to strengthen Fluent’s AI-powered marketplace.” This highlights the vital role that Stack is poised to play in directing investments in data infrastructure and innovative product capabilities.

Transforming Commerce Media

As the landscape of commerce media progresses, the demand for advanced, intelligent solutions grows. Brands are in search of effective ways to reach and convert consumers who demonstrate high intent. Fluent's commitment to investments in AI, identity resolution, and bidding technology underscores its potential to enhance advertisement relevance, which in turn maximizes ROI for advertisers.

Stack's Vision for the Future

Adrian Stack expressed his excitement about the journey ahead at Fluent. He emphasized, “We are building an AI-powered marketplace that seamlessly connects brands with high-value consumers at scale.” His vision includes leveraging Fluent’s proprietary first-party identity graph, along with advanced machine learning models to improve ad relevance and boost conversion rates.

Strengthening Consumer Connections

With a solid background in customer acquisition spanning 14 years, Fluent continues to set itself apart in the commerce media sector through its owned marketplaces and extensive first-party data. Stack is expected to play a pivotal role in refining data strategies, pushing forward product innovation, and uncovering long-term growth and profitability opportunities.

About Fluent, Inc.

Fluent, Inc. (NASDAQ: FLNT) is a pioneering provider of commerce media solutions, acting as a bridge between top brands and highly engaged consumers. Utilizing exclusive ad inventory, vast first-party data, and proprietary machine learning techniques, the company helps unlock new revenue channels for partners while enabling advertisers to reach their most valuable customers effectively. Since its inception in 2010, Fluent has harnessed a wealth of experience in performance marketing to enhance monetization and elevate engagement at pivotal moments throughout the customer journey. For further insights, feel free to explore their website.

Contact Information

Investor Relations
Fluent, Inc.
Email: InvestorRelations@fluentco.com

Frequently Asked Questions

What role has Adrian Stack been appointed to at Fluent, Inc.?

Adrian Stack has been appointed as the Chief Product Officer at Fluent, Inc.

What is the main focus of Fluent, Inc. under Stack's leadership?

The primary focus is on advancing AI-powered Commerce Media Solutions to enhance consumer engagement.

How does Fluent, Inc. differentiate itself in the commerce media industry?

Fluent, Inc. differentiates itself through its owned marketplaces and comprehensive first-party data assets.

What previous experience does Adrian Stack bring to Fluent, Inc.?

Stack has extensive experience in product development, having previously worked at Zillow and Rokt.

How does Fluent, Inc. leverage AI in its operations?

Fluent utilizes AI for identity resolution, bidding technology, and enhancing ad relevance to maximize ROI for advertisers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading